GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Dianthus Therapeutics
The stock of Dianthus, a biotech focused on treating rare immune diseases, reflects the potential of its lead drug. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
The stock of Dianthus, a biotech focused on treating rare immune diseases, reflects the potential of its lead drug. We classify it as a Pharma-Immune company, and the chart below shows the dynamics of this entire segment, where value is dependent on the success of clinical trials.
Broad Market Index - GURU.Markets
Dianthus Therapeutics is a biopharmaceutical company developing drugs to treat rare and severe immunological diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the overall biotech sector.
Change in the price of a company, segment, and market as a whole per day
DNTH - Daily change in the company's share price Dianthus Therapeutics
Shares of Dianthus Therapeutics, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This indicator reflects sensitivity to news about clinical trials. This metric is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Dianthus Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with DNTH, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Dianthus is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Dianthus's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Dianthus Therapeutics
Dianthus is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Dianthus Therapeutics is a biotech company developing innovative drugs for the treatment of rare hematological diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dianthus Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Dianthus Therapeutics
Dianthus, a clinical-stage biotech company specializing in the treatment of rare immunological diseases, has sharp monthly fluctuations reflecting the release of clinical trial data, which is key to its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech company developing antibodies to treat severe and rare autoimmune diseases. Its approach aims to make drug administration more convenient and less frequent. The chart below shows the overall dynamics of the biotech sector, where investors are evaluating the potential of new therapeutic platforms.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing antibodies to treat rare and severe autoimmune diseases. The company's future depends solely on the success of its clinical trials. The broader market chart serves as a contrasting backdrop to how scientific news has driven its stock in its own world.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Dianthus Therapeutics
Shares of Dianthus Therapeutics, a biopharmaceutical company specializing in the treatment of rare immune diseases, reflect the high risks and expectations in biotech each week. The price movement is a response to progress in clinical trials of their next-generation antibodies.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Immunology-focused biotech is a sector where weekly performance is driven by clinical data. The search for new treatments for autoimmune diseases is a common trend across the board. The chart illustrates this backdrop, which allows us to assess the potential of Dianthus Therapeutics.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Dianthus Therapeutics is another biotech company developing drugs to treat immune diseases. Shares of such innovative companies often move independently of the market. This chart will help you understand: is Dianthus living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
DNTH - Market capitalization of the company Dianthus Therapeutics
Dianthus's market capitalization tells the story of an early-stage biotech company focused on developing antibodies to treat rare immunological diseases. Its chart reflects not revenue, but investor confidence in its scientific platform. Its dynamics reflect its progress through clinical trials, where any outcome can dramatically change the valuation.
DNTH - Share of the company's market capitalization Dianthus Therapeutics within the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech developing antibodies for the treatment of rare and severe autoimmune diseases. Its market share reflects the hopes associated with its platform. Its market cap represents a venture bet on future clinical successes and breakthroughs.
Market capitalization of the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech company developing drugs to treat autoimmune diseases. The chart below shows the overall market capitalization of this sector. Its dynamics are a roller coaster, reflecting investor hopes for a scientific breakthrough and the development of a new, effective treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Dianthus Therapeutics is a biotech company developing antibodies to treat rare and severe autoimmune diseases. Its market cap reflects the hope for new, more effective therapies. The chart below shows the share price of the immunology-focused biotech.
Book value capitalization of the company, segment and market as a whole
DNTH - Book value capitalization of the company Dianthus Therapeutics
Dianthus Therapeutics' balance sheet represents its capital invested in developing antibodies for the treatment of rare and severe immunological diseases. This is the real, scientific foundation for creating a new generation of targeted therapy. How is this young biotech asset shaping up? The chart below shows its initial performance.
DNTH - Share of the company's book capitalization Dianthus Therapeutics within the market segment - Pharma immune
Dianthus Therapeutics, a biopharmaceutical company, utilizes cutting-edge laboratory facilities to develop its treatments for rare diseases. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation for the creation of innovative treatments.
Market segment balance sheet capitalization - Pharma immune
Developing drugs to treat rare autoimmune diseases, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. Dianthus Therapeutics operates in this environment, investing its capital in the scientific platform and clinical trials rather than in building factories.
Book value of all companies included in the broad market index - GURU.Markets
Dianthus Therapeutics' assets are not factories, but valuable intellectual capital and research data in the field of rare immune diseases. Its book value reflects its investment in a scientific platform that forms the foundation for the development of a new generation of targeted therapeutics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Dianthus Therapeutics
Dianthus Therapeutics is an early-stage biotech company working on rare diseases. Its balance sheet is all cash. Its market capitalization is pure expectations. The MvsBCap chart here isn't an asset valuation, but a bet on the scientific hypothesis and the team. It will move based on lab news, not financial results.
Market to book capitalization ratio in a market segment - Pharma immune
Dianthus Therapeutics is a biotech company developing drugs to treat rare hematological diseases. Its value is based on the potential of its scientific developments. This chart reflects investor expectations regarding the success of its clinical programs.
Market to book capitalization ratio for the market as a whole
Dianthus Therapeutics is a biotech company developing drugs to treat rare immune diseases. Its value reflects investors' bet on the success of its scientific platform. Book value is largely irrelevant. This chart illustrates how the market values the company's potential to solve complex medical problems.
Debts of the company, segment and market as a whole
DNTH - Company debts Dianthus Therapeutics
Dianthus Therapeutics, a biotech company in early clinical development, uses equity and debt capital exclusively to fund its research activities. This chart shows the financial health of the company, which is entirely focused on developing innovative immunology drugs and currently has no revenue.
Market segment debts - Pharma immune
Dianthus Therapeutics is a biotech company developing treatments for rare and severe immunological diseases. Being in the clinical stage, the company relies entirely on external funding for research. This chart provides insight into its capital structure and fundraising strategy for bringing its drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotech developing therapies for rare autoimmune diseases. The chart shows how the company finances its research. For a biopharma without revenue, debt is a sign of investor faith in its science, but it also represents a significant risk that could materialize if trials are unsuccessful.
Market segment debt to market segment book capitalization - Pharma immune
Dianthus Therapeutics is another early-stage biotech company working in the field of immunology. This chart for the biotech sector illustrates how much venture capital the industry attracts to fund breakthrough ideas. It helps us understand how the company's financial position is typical for this high-risk field.
Debt to book value of all companies in the market
Dianthus Therapeutics is a biotech company. Its funding depends on investor confidence in its future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt or equity financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Dianthus Therapeutics
This chart of Dianthus Therapeutics, a biopharmaceutical company focused on immunology, reflects investors' faith in its scientific approach. Its high stock price reflects the hope that its drugs will successfully pass clinical trials and offer new treatments for patients with rare diseases.
P/E of the market segment - Pharma immune
This chart shows the average price-to-earnings ratio for the biotech sector in which Dianthus Therapeutics operates. The industry's high valuation reflects expectations of future breakthroughs. The chart illustrates this general context, against which investors evaluate the scientific potential and risks associated with Dianthus's immunology developments.
P/E of the market as a whole
Dianthus Therapeutics is a clinical-stage biotech company developing antibodies to treat rare and severe autoimmune diseases. Its approach is aimed at addressing the underlying cause of the disease. This overall risk appetite chart is an indicator of how willing investors are to invest in Dianthus's long-term, capital-intensive research and development.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Dianthus Therapeutics
Dianthus Therapeutics is a biotech company developing antibodies for the treatment of rare and severe autoimmune diseases. The chart reflects investor expectations regarding the clinical success of its developments. Future revenue is entirely dependent on positive trial results and subsequent regulatory approval.
%20P%2FE%20Dianthus%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Dianthus-Therapeutics&v=1772643528865 "Chart of the company's future (projected) P/E Dianthus Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech company developing drugs to treat rare and severe autoimmune diseases. The chart shows average profitability expectations for the sector. It helps understand the level of investor confidence in Dianthus's scientific platform and its potential to create breakthrough drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772643528878 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Dianthus Therapeutics is a biotech company developing drugs to treat rare and severe autoimmune diseases. Its value is based on the potential of its scientific research. This overall risk appetite chart shows how willing investors are to invest in long-term immunology projects, which carry both high risks and high potential rewards.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643528883 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of rare and severe autoimmune diseases. Its financial metrics consist primarily of research and development expenses. This chart shows the company's investment phase, which is focused on developing breakthrough treatments and achieving future commercial value.
Profit of companies in the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech company developing antibodies for the treatment of autoimmune diseases. Its success depends entirely on the results of its research. This chart reflects the overall picture in the immunopharmaceutical sector, where both the development risks and the potential rewards of creating a new, effective drug are high.
Overall market profit
Dianthus Therapeutics is a biotechnology company developing drugs to treat rare immunological diseases. Its prospects depend entirely on the results of clinical trials and scientific progress. The overall economic environment, illustrated by this chart, has no impact on the need for treatment of these diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Dianthus Therapeutics
Dianthus Therapeutics is another clinical-stage biotech company developing drugs for rare and severe autoimmune diseases. Future profits depend on the success of these trials. This chart reflects analysts' speculative predictions for the scientific breakthrough and commercial success of its candidates.
%20profit%20of%20the%20company%20Dianthus%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Dianthus-Therapeutics&v=1772643529078 "Graph of future (projected) profit of the company Dianthus Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Dianthus Therapeutics is a biotech company developing antibodies for the treatment of chronic immune diseases. Its lead candidate targets the complement system, which plays a key role in inflammation. The company's success depends on clinical data. This chart shows revenue projections for the immunopharmaceuticals sector, allowing us to assess the potential of Dianthus's developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772643529086 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Dianthus Therapeutics is a biotech company developing treatments for rare immunological diseases. Its development is entirely dependent on funding and successful clinical trials. This economic outlook affects investors' overall risk appetite and their willingness to invest in biotech.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643529096 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Dianthus Therapeutics
Dianthus Therapeutics is a biotechnology company developing drugs to treat rare and severe immunological diseases. Being in the clinical stage, the company has no stable revenue. The chart reflects investor assessments of the scientific potential of its developments and future commercial success.
P/S market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech company developing next-generation antibodies to treat rare and severe autoimmune diseases. Their goal is to create more effective and patient-friendly treatments. This chart reflects the average revenue estimate for the sector, providing insight into investor expectations for Dianthus's technology.
P/S of the market as a whole
Dianthus Therapeutics is a clinical-stage biotech company developing drugs to treat rare and severe autoimmune diseases. This chart highlights that the valuation of such companies is largely unrelated to current revenue, but rather reflects investors' faith in the scientific platform and the future commercial success of its developments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Dianthus Therapeutics
Dianthus Therapeutics is a biotech company developing antibody-based therapies for the treatment of rare and severe autoimmune diseases. For a clinical-stage company, valuations based on future revenue reflect investor confidence. This chart shows the market's confidence in Dianthus's scientific approach and the commercial potential of its leading drug candidates in this niche.
%20P%2FS%20Dianthus%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Dianthus-Therapeutics&v=1772643529290 "The graph of the company's future (projected) P/S Dianthus Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech developing antibodies to treat rare and severe autoimmune diseases. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the company's scientific potential and its ability to create breakthrough treatments for patients with unmet needs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772643529335 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Dianthus Therapeutics is a clinical-stage biotech company developing drugs to treat rare immune diseases. Its prospects depend on the success of its research. Given the overall revenue projections shown in the chart, Dianthus represents a venture investment in the future of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643529357 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Dianthus Therapeutics
This chart shows the revenue of Dianthus Therapeutics, a biotech company developing drugs to treat rare and severe autoimmune diseases. Being in clinical trials, the company may not have commercial revenue. This figure, if present, likely reflects partnerships or funding rather than sales.
Sales of companies in the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of rare autoimmune diseases. Currently, the company has no sales revenue. Its value is based on the potential of its scientific developments, and its future revenue structure will depend on successful clinical trials and commercialization.
Overall market sales
Dianthus Therapeutics is a biotechnology company developing treatments for rare and severe immunological diseases. Its success depends entirely on scientific innovation and clinical trial results. This overall economics chart does not reflect the specific growth drivers for a company at the forefront of medical science, where the rules of the game are entirely different.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for rare immunological diseases. The company has no commercial revenue yet. This chart illustrates analysts' expectations for the potential future sales of its drugs if they successfully complete clinical trials and receive regulatory approval.
%20sales%20of%20the%20company%20Dianthus%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Dianthus-Therapeutics&v=1772643529452 "Schedule of future (projected) sales of the company Dianthus Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Dianthus Therapeutics is a biotech company developing drugs to treat rare immunological diseases. This chart shows the outlook for the immunology sector. Is market growth expected due to new discoveries in the treatment of complement-mediated diseases? This helps assess the overall potential of Dianthus's field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772643529470 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Dianthus Therapeutics is a clinical-stage biotechnology company developing drugs for the treatment of rare immunological diseases. Its prospects depend entirely on the success of its scientific developments and clinical trials. The macroeconomic trends reflected in this chart are not directly related to the fundamental drivers of the company's value.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643529500 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Dianthus Therapeutics
Dianthus Therapeutics is a biotech company developing antibodies to treat rare and severe autoimmune diseases. This chart reflects its financial position at the preclinical and early clinical trial stages. Profitability is a long-term goal, and current figures reflect the level of investment in developing next-generation immunotherapeutics.
Market segment marginality - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech developing drugs to treat rare immunological diseases. Like other companies at this stage, it does not generate revenue and is actively investing in research. This chart shows its current financial metrics, where profitability is a long-term goal dependent on R&D success.
Market marginality as a whole
Dianthus Therapeutics is a biotechnology company developing treatments for rare and severe autoimmune diseases. Its development requires significant and long-term investment in research and development. This total return chart reflects the investment climate and market willingness to fund innovative, yet risky, biotechnology projects.
Employees in the company, segment and market as a whole
Number of employees in the company Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotech company developing drugs for the treatment of rare immunological diseases. Its very small staff consists of key scientists and managers. This schedule is typical for early-stage startups: the team will grow as the company raises funding and advances its research.
Share of the company's employees Dianthus Therapeutics within the market segment - Pharma immune
Dianthus Therapeutics is a biotechnology company developing next-generation antibodies to treat rare and severe autoimmune diseases. Its activities are focused on laboratory and clinical research. This graph shows the company's labor market share, and its value reflects its stage of development as an R&D-focused company competing for scientific talent.
Number of employees in the market segment - Pharma immune
Dianthus Therapeutics is a biopharmaceutical company developing antibodies for the treatment of rare and severe complement-mediated diseases. This chart shows the company's employment in the immunopharmaceutical sector. Dianthus's focus on specific immune system proteins could lead to the creation of a new class of drugs for patients with limited treatment options.
Number of employees in the market as a whole
Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare immunological diseases. Its small but growing staff of scientists and doctors is a bet on future medical breakthroughs. Compared to overall employment, hiring here reflects not the current state of the economy, but rather investors' faith in science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Dianthus Therapeutics (DNTH)
Dianthus Therapeutics is a biotech company. This chart is a clear example of how the market values science. All value can be concentrated in a single promising molecule. The astronomical market capitalization per employee reflects not current revenue, but rather investors' faith in the future breakthrough that a small team of scientists can create.
%20of%20the%20company%20Dianthus%20Therapeutics%20(DNTH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Dianthus-Therapeutics-DNTH&v=1772643529936 "Chart of market capitalization per employee (in thousands of dollars) of the company Dianthus Therapeutics (DNTH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Dianthus Therapeutics (DNTH) is a clinical-stage biotech developing antibodies to treat rare immunological diseases. It is an R&D-focused business. This chart shows the average market capitalization per employee in the sector. It helps assess the market premium for their scientific platform, based on their small staff of scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772643530017 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Dianthus Therapeutics is a clinical-stage biotech developing drugs for the treatment of rare hematological diseases. Like other biotechs without revenue, its valuation is based on expectations. The chart shows a high valuation per employee, as investors believe in the scientific platform and the potential of its developments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643530197 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Dianthus Therapeutics (DNTH)
Dianthus is a clinical-stage biotech company developing drugs to treat rare immune diseases. This chart, like many biotech companies, shows the investment phase. Negative profit per employee means that each scientist is a cost center, funded by investors for future commercialization.
%20Chart%20Dianthus%20Therapeutics%20(DNTH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Dianthus-Therapeutics-DNTH&v=1772643530266 "Company Profit Per Employee (in thousands of dollars) Chart Dianthus Therapeutics (DNTH)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Dianthus (DNTH) is an R&D biotech (immunology). This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772643530326 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Dianthus Therapeutics is a clinical-stage biotech company specializing in immunology (rare diseases). It's an R&D company. Like Vera or Celldex, this chart shows the operating loss per employee—the "cost" of conducting expensive clinical trials per research staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643530417 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Dianthus Therapeutics (DNTH)
Dianthus Therapeutics is a biotech company focused on immunology. At the current stage of drug development, revenue per employee is likely nonexistent. However, this graph is important for future assessments: a successful drug could generate enormous revenue, leading to explosive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Dianthus-Therapeutics-DNTH&v=1772643530434 "Sales chart per company employee Dianthus Therapeutics (DNTH)")
Sales per employee in the market segment - Pharma immune
Dianthus Therapeutics is a clinical-stage biotech company developing therapies for rare immunological diseases. This is pure R&D. This chart shows the average output in the sector. As with other R&D biotechs, it is more of a leading indicator of the efficiency of capital utilization (personnel costs) for advancing development.
Sales per employee for the market as a whole
Dianthus Therapeutics is a clinical-stage biotech company specializing in rare immunological diseases. The company has no sales revenue during the R&D phase. This chart reflects ongoing investments in the scientific team working on the development of future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Dianthus Therapeutics (DNTH)
Dianthus Therapeutics (DNTH) is a clinical-stage biotech developing therapies for rare autoimmune diseases. This chart shows the number of short positions. Like other biotechs without revenue, short positions represent a bet that their scientific approach will fail or that clinical trials will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Dianthus-Therapeutics-DNTH&v=1772643530540 "Short Shares Chart for the Company Dianthus Therapeutics (DNTH)")
Shares shorted by market segment - Pharma immune
Dianthus Therapeutics (DNTH) is a clinical-stage biotech developing antibodies to treat rare immunological diseases. This chart aggregates short positions across the entire biotech sector. It reflects investor skepticism regarding the risks of clinical trials and funding difficulties.
Shares shorted by the overall market
Dianthus (DNTH) is a clinical-stage biotech (immunology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives DNTH of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Dianthus Therapeutics (DNTH)
Dianthus Therapeutics (DNTH) is a clinical-stage biotech developing antibodies to treat rare autoimmune diseases. Their success is entirely dependent on R&D. This chart measures speculative interest. It shows "overheated" (above 70) during positive trial data or "oversold" (below 30) during lulls or trial failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Dianthus-Therapeutics-DNTH&v=1772643530691 "RSI 14 indicator chart for the company's stock Dianthus Therapeutics (DNTH)")
RSI 14 Market Segment - Pharma immune
Dianthus Therapeutics (DNTH) is a biotech company developing antibodies to treat rare immune diseases. The RSI_14_Seg for "Pharma immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether DNTH's volatility is a reaction to its trials or simply general hype in the sector.
RSI 14 for the overall market
Dianthus Therapeutics (DNTH) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DNTH (Dianthus Therapeutics)
Dianthus Therapeutics is a clinical-stage biotech developing treatments for rare immunological diseases. Their approach is aimed at inhibiting complement. This chart shows the analysts' average 12-month forecast, representing their collective, speculative bet on the success of their ongoing clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DNTH-Dianthus-Therapeutics&v=1772643530814 "A chart showing analyst consensus forecasts for the expected stock price. DNTH (Dianthus Therapeutics)")
The difference between the consensus estimate and the actual stock price DNTH (Dianthus Therapeutics)
Dianthus Therapeutics is a biotech company developing a new generation of antibodies to treat rare immunological diseases. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the consensus price forecast and the current price, reflecting confidence in their scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DNTH-Dianthus-Therapeutics&v=1772643530830 "A chart showing the difference between the consensus forecast and the actual stock price. DNTH (Dianthus Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Dianthus Therapeutics is a biotech company focused on developing novel antibodies to treat severe autoimmune diseases. This chart shows analysts' overall expectations across the immunology sector. It reflects whether experts believe in the potential of next-generation targeted therapies for inflammation.
Analysts' consensus forecast for the overall market share price
Dianthus Therapeutics (DNTH) is a clinical-stage biopharmaceutical company developing drugs to treat rare immunological diseases. This is a venture capital investment in science. This chart shows the overall risk appetite in the market and serves as an indicator of the open or closed funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotech focused on developing antibodies to treat rare immune diseases. This chart represents pure R&D performance. It likely reflects investors' confidence in successful clinical trials, their scientific platform, and the market potential of their lead drug candidates, rather than revenue.
AKIMA Market Segment Index - Pharma immune
Dianthus Therapeutics (DNTH) is a clinical-stage biotech focused on immunology; the company is developing next-generation antibodies (complement inhibitors) for the treatment of rare autoimmune diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (DNTH) differentiate it from the average pharma company?
The AKIM Index for the overall market
Dianthus Therapeutics is a biotech company developing new treatments for autoimmune diseases through complement inhibition. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story, fueled by trial data, compares to overall economic trends.
